Embolic stroke in aged rats treated with thymosin beta4
How the study was set up
Older male rats were randomized after an experimental embolic stroke to full-length thymosin beta4 or control, with follow-up through 56 days.
What the researchers measured
Infarct volume, neurological and motor tests, myelin-related changes, and glial-cell staining were measured.
How to read this evidence
Researchers studied cells, isolated tissue, or animals. These experiments can help explain a mechanism, but do not establish benefits or safety in people. Human cells grown in a laboratory also belong in this category.
Results in context
Infarct volume decreased, but functional outcomes did not improve. This negative functional finding is central to interpreting the paper and differs from results in younger animal models.
What this does not establish
The negative functional result matters: reduced lesion size did not translate into measured recovery. This does not establish human stroke treatment or TB-500 efficacy.
This collection includes related thymosin beta4 research. Parent or engineered peptide findings do not establish that a TB-500 fragment or a product sold under that name has the same effects.
Publication & source
Why this paper is included
The title focuses on thymosin beta4 or TB-500; parent-peptide findings do not establish TB-500 fragment effects.